自从动物实验证实醛糖还原酶(AR)可诱发大白鼠糖性白内障以来,醛糖还原酶抑制剂(ARI)便被作为一种治疗人糖尿病性眼部合并症的新药,开始受到重视。但本文作者认为,临床上判断ARI的疗效既复杂而又困难,因此,有必要通过动物实验进一步加以验证。作者所用的方法是,选择体重约200克的SD系大白鼠,按50mg/kg的剂量从尾静脉注入链脲霉素后,半数大白鼠再给予混合有 Since animal experiments confirmed that aldose reductase (AR) can induce glycated cataract in rats, aldose reductase inhibitors (ARIs) are being used as a new drug for the treatment of human diabetic ocular complications and are beginning to be valued. However, the authors believe that the curative effect of ARI in clinical judgment is complicated and difficult, therefore, it is necessary to further verify by animal experiments. The method used by the authors was to select SD rats weighing about 200 grams and inject streptozotocin at a dose of 50 mg / kg into the caudal vein. Half of the rats were then given a mixture of